Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 238 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

GLP_1 RA Ultrasound Study

NCT06581120
Conditions
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
Interventions
Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chula Vista, California • Escondido, California • Renton, Washington
Conditions
Obesity or Overweight
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

NCT07141472
Conditions
Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
Interventions
GB, Placebo
Dietary Supplement
Lead sponsor
Lawry Han
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post Bariatric Closed Loop Glucagon Trial

NCT02966275
Conditions
Hypoglycemia
Interventions
Glucagon-only bionic pancreas - glucagon, Glucagon-only bionic pancreas - placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
Interventions
RDX-002, Placebo
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saint Paul, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
CJC-1134-PC Injection, Weekly placebo for CJC-1134-PC Injection
Drug
Lead sponsor
ConjuChem
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Inglewood, California • Tarzana, California + 16 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type1 Diabetes Mellitus
Interventions
Glucagon-like peptide-1, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Gastric Bypass Surgery, Obesity
Interventions
Liquid Meal, Solid Meal
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

NCT06333496
Conditions
Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity, Heart Health Markers
Interventions
GLP-1 Booster (GB)
Dietary Supplement
Lead sponsor
Alpine Biotech LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hyperglycemia Drug Induced
Interventions
REMD-477
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Completed Phase 2 Interventional Results available

G-Pen™ for Hypoglycemia Rescue in T1D Patients

NCT02423980
Conditions
Hypoglycemia
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Weight Maintenance
Interventions
Digital Behavioral Application
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypoglycemia, Type1diabetes
Interventions
Fasting, Feeding
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Type 2 Diabetes Mellitus
Interventions
LGD-6972, Placebo (Captisol®)
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-Loop Glucagon Administration For Hypoglycemia Treatment

NCT02181127
Conditions
Type 1 Diabetes
Interventions
Glucagon-only Bionic Pancreas
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri